Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient was on low-dose aspirin treatment on the day when consent was obtained, and requires the long-term continuous treatment even after treatment with the investigational drug is started.~* The patient was confirmed to have a history of gastric ulcer or duodenal ulcer.~Exclusion Criteria:~* Endoscopically confirmed gastric and/or duodenal ulcers on Day 1.~* Endoscopically confirmed active upper gastrointestinal hemorrhage on Day 1.~* Current or past history of aspirin-induced asthma or hypersensitivity to nonsteroidal anti-inflammatory drugs.~* Past or planned surgery affecting gastric acid secretion.~* Clinically significant hepatic or renal disorder.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lansoprazole 15 mg QD (Type: EXPERIMENTAL): None
- Gefarnate 50 mg BID (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).